Selectively targeting the toll-like receptor 9 (TLR9) - IRF 7 signaling pathway by polymer blend particles

Biomaterials

Volumn 34, Issue 27, 2013, Pages 6464-6472

  Chen, Helen C ^a   Zhan, Xi ^a   Tran, Kenny K ^a   Shen, Hong ^a  

^a University of Washington   (United States)

Author keywords

Apoptosis; Carcinogenesis; Immunotherapy; Inflammation; PH sensitive polymer

Indexed keywords

CARCINOGENESIS; CPG OLIGONUCLEOTIDES; IMMUNOTHERAPY; INFLAMMATION; PH SENSITIVE; PH-SENSITIVE COPOLYMERS; PRO-INFLAMMATORY CYTOKINES; SELECTIVE ACTIVATION;

CHEMICAL ACTIVATION; OLIGONUCLEOTIDES; ONCOLOGY; PATHOLOGY; PIGMENTS; SIGNALING; TUMORS;

CELL DEATH;

2 (DIMETHYLAMINO)ETHYL METHACRYLIC ACID; 2 PROPYLACRYLIC ACID; ALPHA INTERFERON; BUTYL METHACRYLIC ACID; COPOLYMER; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; MONOMER; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG TARGETING; GENE TARGETING; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARTICLE SIZE; PH; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURFACE CHARGE; TRANSCRIPTION INITIATION; ZETA POTENTIAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; CYTOKINES; HUMANS; HYDROGEN-ION CONCENTRATION; INTERFERON REGULATORY FACTOR-7; MICE; MICE, INBRED C57BL; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9;

EID: 84879124007     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.016     Document Type: Article

References (51)

1. Krieg A.M. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
2. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. Atoll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
3. Krug A., Luker G.D., Barchet W., Leib D.A., Akira S., Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004, 103:1433-1437.
4. Lund J., Sato A., Akira S., Medzhitov R., Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. JExp Med 2003, 198:513-520.
5. Krug A., French A.R., Barchet W., Fischer J.A.A., Dzionek A., Pingel J.T., et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004, 21:107-119.
6. Ramirez-Ortiz Z.G., Specht C.A., Wang J.P., Lee C.K., Bartholomeu D.C., Gazzinelli R.T., et al. Toll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNA. Infect Immun 2008, 76:2123-2129.
7. Nakamura K., Miyazato A., Xiao G., Hatta M., Inden K., Aoyagi T., et al. Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. JImmunol 2008, 180:4067-4074.
8. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. JClin Invest 2005, 115:407-417.
9. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., et al. Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. JExp Med 2005, 202:1131-1139.
10. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature 2002, 416:603-607.
11. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. JExp Med 2004, 199:1631-1640.
12. Kandimalla E.R., Bhagat L., Li Y.K., Yu D., Wang D., Cong Y.P., et al. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A 2005, 102:6925-6930.
13. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
14. Krieg A.M. CpG still rocks! update on an accidental drug. Nucleic Acid Ther 2012, 22:77-89.
15. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004, 5:190-198.
16. Ewald S.E., Lee B.L., Lau L., Wickliffe K.E., Shi G.P., Chapman H.A., et al. The ectodomain of toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658-662.
17. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
18. Honda K., Yanai H., Takaoka A., Taniguchi T. Regulation of the type IIFN induction: a current view. Int Immunol 2005, 17:1367-1378.
19. Aggarwal B.B. Nuclear factor-kappa-B: the enemy within. Cancer Cell 2004, 6:203-208.
20. Karin M., Greten F.R. NF kappa B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759.
21. Dolcet X., Llobet D., Pallares J., Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005, 446:475-482.
22. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj-Vadhan S., et al. Nuclear factor-kappa B and STAT3 are constitutively active in CD138(+) cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004, 103:3175-3184.
23. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. JBiol Chem 2002, 277:16639-16647.
24. Giri D.K., Aggarwal B.B. Constitutive activation of NF-kappa B causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells - autocrine role of tumor necrosis factor and reactive oxygen intermediates. JBiol Chem 1998, 273:14008-14014.
25. Rabi T., Shukla S., Gupta S. Betulinic acid suppresses constitutive and TNF alpha-induced NF-kappa B activation and induces apoptosis in human prostate carcinoma PC-3 cells. Mol Carcinog 2008, 47:964-973.
26. Biswas D.K., Shi Q., Baily S., Strickland I., Ghosh S., Pardee A.B., et al. NF-KB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004, 101:10137-10142.
27. Chiron D., Pellat-Deceunynck C., Amiot M., Bataille R., Jego G. TLR3 ligand induces NF-kappa B activation and various fates of multiple myeloma cells depending on IFN-alpha production. JImmunol 2009, 182:4471-4478.
28. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., et al. Host type I IFN signals are required for antitumor CD8(+) T cell responses through CD8 alpha(+) dendritic cells. JExp Med 2011, 208:2005-2016.
29. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. JExp Med 2011, 208:1989-2003.
30. Lorenzi S., Mattei F., Sistigu A., Bracci L., Spadaro F., Sanchez M., et al. Type I IFNs control antigen retention and survival of CD8 alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. JImmunol 2011, 186:5142-5150.
31. Swann J.B., Hayakawa Y., Zerafa N., Sheehan K.C.F., Scott B., Schreiber R.D., et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. JImmunol 2007, 178:7540-7549.
32. Bidwell B.N., Slaney C.Y., Withana N.P., Forster S., Cao Y., Loi S., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012, 18. 1224-+.
33. Chen H.C., Sun B.B., Tran K.K., Shen H. Effects of particle size on toll-like receptor 9-mediated cytokine profiles. Biomaterials 2011, 32:1731-1737.
34. Takeda N., Nakamura E., Yokoyama M., Okano T. Temperature-responsive polymeric carriers incorporating hydrophobic monomers for effective transfection in small doses. JControl Release 2004, 95:343-355.
35. Ferrito M.T., Tirrell D.A. Poly(2-ethylacrylic acid). Macromol Synth 1992, 11:59-62.
36. Tran K.K., Shen H. The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells. Biomaterials 2009, 30:1356-1362.
37. Dalod M., Salazar-Mather T.P., Malmgaard L., Lewis C., Asselin-Paturel C., Briere F., et al. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression invivo. JExp Med 2002, 195:517-528.
38. Grainger S.J., Mohamed E.H.El-Sayed Stimuli-sensitive particles for drug delivery. Biologically-responsive hybrid biomaterials 2010, 171-190. World Scientific Publishing, Singapore.
39. van de Wetering P., Moret E.E., Schuurmans-Nieuwenbroek N.M.E., van Steenbergen M.J., Hennink W.E. Structure-activity relationships of water-soluble cationic methacrylate/methacrylamide polymers for nonviral gene delivery. Bioconjug Chem 1999, 10:589-597.
40. Convertine A.J., Benoit D.S.W., Duvall C.L., Hoffman A.S., Stayton P.S. Development of a novel endosomolytic diblock copolymer for siRNA delivery. JControl Release 2009, 133:221-229.
41. Shen H., Ackerman A.L., Cody V., Giodini A., Hinson E.R., Cresswell P., et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006, 117:78-88.
42. Yanagawa Y., Iijima N., Iwabuchi K., Onoe K. Activation of extracellular signal-related kinase by TNF-alpha controls the maturation and function of murine dendritic cells. JLeukoc Biol 2002, 71:125-132.
43. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R.T., Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003, 300:1148-1151.
44. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., et al. IKK epsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003, 4:491-496.
45. Sato M., Suemori H., Hata N., Asagiri M., Ogasawara K., Nakao K., et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000, 13:539-548.
46. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments. Eur J Immunol 2002, 32:1958-1968.
47. Bell J.K., Botos I., Hall P.R., Askins J., Shiloach J., Segal D.M., et al. The molecular structure of the toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci U S A 2005, 102:10976-10980.
48. Choe J., Kelker M.S., Wilson I.A. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 2005, 309:581-585.
49. Bell J.K., Askins J., Hall P.R., Davies D.R., Segal D.M. The dsRNA binding site of human toll-like receptor 3. Faseb J 2006, 20:A96-A.
50. Liu L., Botos I., Wang Y., Leonard J.N., Shiloach J., Segal D.M., et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008, 320:379-381.
51. Peter M.E., Kubarenko A.V., Weber A.N.R., Dalpke A.H. Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation. JImmunol 2009, 182:7690-7697.